Clinical perspectives on the use of composite endpoints (Q41668413)

6 October 2017

1 reference

title

Clinical perspectives on the use of composite endpoints (English)

1 reference

6 October 2017

Cannon CP

1

1 reference

PubMed ID

9408715

6 October 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

Contemporary Clinical Trials

6 October 2017

1 reference

6 October 2017

18

1 reference

6 October 2017

6

1 reference

6 October 2017

517-29; discussion 546-9

1 reference

Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction - Comparison with conventionally treated patients

6 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Intracoronary thrombolysis in evolving myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Evaluation of the effectiveness of intracoronary streptokinase infusion in acute myocardial infarction: postprocedure management and hospital course in 204 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

A Randomized Trial of Intracoronary Streptokinase in the Treatment of Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

The open-artery theory is alive and well--again

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Significance of a coronary artery with Thrombolysis in Myocardial infarction grade 2 flow “patency” (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

The effect of warfarin on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Long-term survival in 618 patients from the Western Washington streptokinase in myocardial infarction trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Reduction of Infarct Size with the Early Use of Timolol in Acute Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Risk stratification and survival after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the myocardial infarction triage and intervention project)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2897%2900005-6

7 January 2021

10.1016/S0197-2456(97)00005-6

Identifiers

DOI

1 reference

6 October 2017

1 reference

PubMed ID

9408715